Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To determine the prognostic value of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 in gallbladder cancer (GBC) during palliative chemotherapy. Methods: One hundred and twenty-three patients with pathologically confirmed unresectable GBC were included. Differences in serum CEA and CA 19-9 levels before and after chemotherapy were measured. Receiver operating characteristic curve analysis, Kaplan-Meier analyses of CEA, CA 19-9, and combined changes were performed to assess the optimal cutoff values and survival rates. Results: Patients with decreased tumor markers had significantly better progression-free survival (PFS) and overall survival (OS) than patients with increased tumor markers. The pre- and postchemotherapy CA 19-9 ratio had the highest area-under-the-curve values for predicting 3-month PFS and 1-year OS. In the multivariate analysis, increases in serum CA 19-9 during palliative chemotherapy in patients with unresectable GBC was an independent prognosticator of poor PFS and OS, with hazard ratios of 2.20 (p=0.001) and 1.67 (p=0.020), respectively. Patients with increases >10-fold were considered to have progressive disease, whereas individuals with increases >3-fold were likely to benefit from early imaging follow-up. Conclusions: CA 19-9 kinetics was a reliable prognosticator of PFS and OS in patients with unresectable GBC who underwent palliative chemotherapy.
Abstract
Background/Aims: To determine the prognostic value of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 in gallbladder cancer (GBC) during palliative chemotherapy. Methods: One hundred and twenty-three patients with pathologically confirmed unresectable GBC were included. Differences in serum CEA and CA 19-9 levels before and after chemotherapy were measured. Receiver operating characteristic curve analysis, Kaplan-Meier analyses of CEA, CA 19-9, and combined changes were performed to assess the optimal cutoff values and survival rates. Results: Patients with decreased tumor markers had significantly better progression-free survival (PFS) and overall survival (OS) than patients with increased tumor markers. The pre- and postchemotherapy CA 19-9 ratio had the highest area-under-the-curve values for predicting 3-month PFS and 1-year OS. In the multivariate analysis, increases in serum CA 19-9 during palliative chemotherapy in patients with unresectable GBC was an independent prognosticator of poor PFS and OS, with hazard ratios of 2.20 (p=0.001) and 1.67 (p=0.020), respectively. Patients with increases >10-fold were considered to have progressive disease, whereas individuals with increases >3-fold were likely to benefit from early imaging follow-up. Conclusions: CA 19-9 kinetics was a reliable prognosticator of PFS and OS in patients with unresectable GBC who underwent palliative chemotherapy.
참고문헌 (23)
- Howlader N, "SEER cancer statistics review, 1975-2013", National Cancer Institute, ~ (2015)
- Sharma A, "Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study", J Clin Oncol, 28, pp.4581~4586 (2010)[DOI]
- 박준오, "Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review", Cancer Research and Treatment, 47(3), pp.343~361 (2015), 대한암학회[DOI]
- Grunnet M, "Serum tumor markers in bile duct cancer: a review", Biomarkers, 19, pp.437~443 (2014)[DOI]
- Vainshtein JM, "Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1", 2 dose escalation study, 2013, pp.86, 96~101
- Ziske C, "Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine", Br J Cancer, 89, pp.1413~1417 (2003)[DOI]
- Haas M, "Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy", J Cancer Res Clin Oncol, 139, pp.681~689 (2013)[DOI]
- Ko AH, "Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer", Br J Cancer, 93, pp.195~199 (2005)[DOI]
- Lee BS, "Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma", J Gastroenterol Hepatol, 31, pp.493~500 (2016)[DOI]
- Shukla VK, "Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder", Trop Gastroenterol, 27, pp.160~165 (2006)
- Rana S, "Evaluation of CA 242 as a tumor marker in gallbladder cancer", J Gastrointest Cancer, 43, pp.267~271 (2012)[DOI]
- Wang YF, "Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer", World J Gastroenterol, 20, pp.4085~4092 (2014)[DOI]
- Huang L, "Serum CYFRA 21-1 in biliary tract cancers: a reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma", Dig Dis Sci, 60, pp.1273~1283 (2015)[DOI]
- Yu T, "Preoperative prediction of survival in resectable gallbladder cancer by a combined utilization of CA 19-9 and carcinoembryonic antigen", Chin Med J (Engl), 127, pp.2299~2303 (2014)
- Jeong Y, "Postoperative radiotherapy for gallbladder cancer", Anticancer Res, 34, pp.5621~5629 (2014)
- Noshiro H, "Factors affecting surgical outcome for gallbladder carcinoma", Hepatogastroenterology, 50, pp.939~944 (2003)
- Shukla PJ, "A new scoring system for gallbladder cancer (aiding treatment algorithm): an analysis of 335 patients", Ann Surg Oncol, 15, pp.3132~3137 (2008)[DOI]
- Fernandez-Ruiz M, "Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma", World J Gastroenterol, 15, pp.5279~5286 (2009)[DOI]
- Sun XN, "Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma", Tumour Biol, 32, pp.1183~1190 (2011)[DOI]
- Kwon YJ, "Is T-stage the only significant factor determining the extent of surgery for gallbladder cancer?", Hepatogastroenterology, 61, pp.304~306 (2014)
- Chakravarty KD, "Factors influencing long-term survival in patients with T3 gallbladder adenocarcinoma", Digestion, 79, pp.151~157 (2009)[DOI]
- Ong SL, "Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration", Dig Dis Sci, 53, pp.3213~3217 (2008)[DOI]
- Kim YC, "Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?", J Gastroenterol Hepatol, 24, pp.1869~1875 (2009)[DOI]